[
  {
    "ts": null,
    "headline": "Why AbbVie Stock Topped the Market Today",
    "summary": "A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (NYSE: ABBV) stock an investor darling on Friday.  The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the bellwether S&P 500 index it's a part of.  For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.",
    "url": "https://finnhub.io/api/news?id=a3d34edd8e9bede26edcfe239ee2c71f19e5260cd61d1bfe60e4f54dc71e5c1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745615846,
      "headline": "Why AbbVie Stock Topped the Market Today",
      "id": 134104521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (NYSE: ABBV) stock an investor darling on Friday.  The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the bellwether S&P 500 index it's a part of.  For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.",
      "url": "https://finnhub.io/api/news?id=a3d34edd8e9bede26edcfe239ee2c71f19e5260cd61d1bfe60e4f54dc71e5c1a"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Inc. (ABBV) the Best Dividend Stock to Buy for Long-Term Passive Income?",
    "summary": "We recently published a list of the 15 Best Dividend Stocks to Buy for Long-Term Passive Income. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend stocks for long-term income. Passive income, which refers to money earned with little ongoing effort, was once largely the […]",
    "url": "https://finnhub.io/api/news?id=e2478a83624fcd99749d7250fb1b65a26b680ba454ea8d0d8f02b561d56a8fbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745613480,
      "headline": "Is AbbVie Inc. (ABBV) the Best Dividend Stock to Buy for Long-Term Passive Income?",
      "id": 134104522,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published a list of the 15 Best Dividend Stocks to Buy for Long-Term Passive Income. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend stocks for long-term income. Passive income, which refers to money earned with little ongoing effort, was once largely the […]",
      "url": "https://finnhub.io/api/news?id=e2478a83624fcd99749d7250fb1b65a26b680ba454ea8d0d8f02b561d56a8fbb"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index up 0.3% and th",
    "url": "https://finnhub.io/api/news?id=2194509d8e382ece2d670378c989e487f59a31cc1778bdc3e63f193513fc7a20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745611360,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 134104523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index up 0.3% and th",
      "url": "https://finnhub.io/api/news?id=2194509d8e382ece2d670378c989e487f59a31cc1778bdc3e63f193513fc7a20"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Reports US$13 Billion Sales, Submits Application For New Neurotoxin",
    "summary": "AbbVie (NYSE:ABBV) recently announced its first-quarter earnings, reporting increased sales year-on-year while experiencing a decline in net income and earnings per share. Alongside this, the submission of a Biologics License Application for TrenibotulinumtoxinE marked a significant product announcement. Over the last quarter, AbbVie's stock price moved by 6%, a period that also saw broader market gains driven by a wave of corporate earnings and optimism around potential tariff negotiations...",
    "url": "https://finnhub.io/api/news?id=a3ac84fe12b410879f7c680b82ac852dc0300380906df92c2b2b04217684fa85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745603613,
      "headline": "AbbVie (NYSE:ABBV) Reports US$13 Billion Sales, Submits Application For New Neurotoxin",
      "id": 134094766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) recently announced its first-quarter earnings, reporting increased sales year-on-year while experiencing a decline in net income and earnings per share. Alongside this, the submission of a Biologics License Application for TrenibotulinumtoxinE marked a significant product announcement. Over the last quarter, AbbVie's stock price moved by 6%, a period that also saw broader market gains driven by a wave of corporate earnings and optimism around potential tariff negotiations...",
      "url": "https://finnhub.io/api/news?id=a3ac84fe12b410879f7c680b82ac852dc0300380906df92c2b2b04217684fa85"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up as AbbVie Rises on Earnings -- Health Care Roundup",
    "summary": "Health-care companies rose as earnings continued to come in strong. AbbVie shares rose after the drugmaker posted earnings ahead of Wall Street targets. Merck shares rallied as traders...",
    "url": "https://finnhub.io/api/news?id=4dc5ac7671dd28957cad65644ecb6dd84ee62691c7d1be1e34f38c53522accc2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745602267,
      "headline": "Health Care Up as AbbVie Rises on Earnings -- Health Care Roundup",
      "id": 134096169,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Health-care companies rose as earnings continued to come in strong. AbbVie shares rose after the drugmaker posted earnings ahead of Wall Street targets. Merck shares rallied as traders...",
      "url": "https://finnhub.io/api/news?id=4dc5ac7671dd28957cad65644ecb6dd84ee62691c7d1be1e34f38c53522accc2"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View",
    "summary": "ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.",
    "url": "https://finnhub.io/api/news?id=ca53941b6ce7d980c6f76150534f73f7e737d5f026a4a22a0fa575ec61bf51de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745601480,
      "headline": "AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View",
      "id": 134094767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.",
      "url": "https://finnhub.io/api/news?id=ca53941b6ce7d980c6f76150534f73f7e737d5f026a4a22a0fa575ec61bf51de"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's First Quarter Beat And Raise Leaves Room For More",
    "summary": "AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future expansions expected. Click to read my ABBV update.",
    "url": "https://finnhub.io/api/news?id=295b73efa62429d037f2fc79671041f9d54a41838edf266945a25b43a333b712",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745601428,
      "headline": "AbbVie's First Quarter Beat And Raise Leaves Room For More",
      "id": 134096174,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156297091/image_2156297091.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future expansions expected. Click to read my ABBV update.",
      "url": "https://finnhub.io/api/news?id=295b73efa62429d037f2fc79671041f9d54a41838edf266945a25b43a333b712"
    }
  },
  {
    "ts": null,
    "headline": "Bitcoin extends rally, AbbVie earnings beat, Phillips 66 miss",
    "summary": "As part of today's Market Minute, Julie Hyman examines some of the top stories investors are watching. Bitcoin (BTC-USD) climbs above the $95,000 mark as investors weigh macroeconomic uncertainties. AbbVie (ABBV) stock gains after reporting strong first quarter results and lifting its 2025 profit forecast. Phillips 66 (PSX) shares fall after announcing a wider-than-expected loss in the first quarter. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=f71ab5f0e3add4ede31865a05a092e0dbfead7bda128d20b7d80334812abae6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745601097,
      "headline": "Bitcoin extends rally, AbbVie earnings beat, Phillips 66 miss",
      "id": 134094768,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As part of today's Market Minute, Julie Hyman examines some of the top stories investors are watching. Bitcoin (BTC-USD) climbs above the $95,000 mark as investors weigh macroeconomic uncertainties. AbbVie (ABBV) stock gains after reporting strong first quarter results and lifting its 2025 profit forecast. Phillips 66 (PSX) shares fall after announcing a wider-than-expected loss in the first quarter. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=f71ab5f0e3add4ede31865a05a092e0dbfead7bda128d20b7d80334812abae6b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift",
    "summary": "AbbVie shares rose Friday after the drugmaker's first-quarter results came in above analysts' expectations.",
    "url": "https://finnhub.io/api/news?id=37846b962d322f52208df8468c0426c2ced5fb2a803101a65034a9e0e78719b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745599766,
      "headline": "AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift",
      "id": 134094769,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie shares rose Friday after the drugmaker's first-quarter results came in above analysts' expectations.",
      "url": "https://finnhub.io/api/news?id=37846b962d322f52208df8468c0426c2ced5fb2a803101a65034a9e0e78719b5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Hikes Its Outlook On The Back Of Two Powerhouse Drugs",
    "summary": "AbbVie Hikes Its Outlook On The Back Of Two Powerhouse Drugs",
    "url": "https://finnhub.io/api/news?id=5336549c0cb811fd95e4f9ae58ab394b8181a9dcff1fe51a518be3b53bbe740b",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745597134,
      "headline": "AbbVie Hikes Its Outlook On The Back Of Two Powerhouse Drugs",
      "id": 134127417,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "AbbVie Hikes Its Outlook On The Back Of Two Powerhouse Drugs",
      "url": "https://finnhub.io/api/news?id=5336549c0cb811fd95e4f9ae58ab394b8181a9dcff1fe51a518be3b53bbe740b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts",
    "summary": "First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts’ expectations.",
    "url": "https://finnhub.io/api/news?id=f8da3400ca6edd27221360d8af8a03b0c9996ebcb3cc942193c083350209d5bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745596980,
      "headline": "AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts",
      "id": 134094770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts’ expectations.",
      "url": "https://finnhub.io/api/news?id=f8da3400ca6edd27221360d8af8a03b0c9996ebcb3cc942193c083350209d5bc"
    }
  },
  {
    "ts": null,
    "headline": "Drugmaker Abbvie Ramps Up Domestic Manufacturing Plans on Tariff Threats",
    "summary": "Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, including building four new plants. The pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.",
    "url": "https://finnhub.io/api/news?id=c81656ab7148c1eaba7625d7ea76dadb00a7063411c66ade68d3a80101a4d82b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745596975,
      "headline": "Drugmaker Abbvie Ramps Up Domestic Manufacturing Plans on Tariff Threats",
      "id": 134094771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, including building four new plants. The pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.",
      "url": "https://finnhub.io/api/news?id=c81656ab7148c1eaba7625d7ea76dadb00a7063411c66ade68d3a80101a4d82b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q1 Earnings Reinforce Positive Momentum",
    "summary": "AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more on ABBV earnings update.",
    "url": "https://finnhub.io/api/news?id=2d5e4b04a5ac5e407c51416adbb69373ff8835c4fe5385795837a15bc353363a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745596804,
      "headline": "AbbVie: Q1 Earnings Reinforce Positive Momentum",
      "id": 134095648,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more on ABBV earnings update.",
      "url": "https://finnhub.io/api/news?id=2d5e4b04a5ac5e407c51416adbb69373ff8835c4fe5385795837a15bc353363a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie warns of tariff exposure, U.S. policy risks while boosting forecast",
    "summary": "Investing.com -- AbbVie Inc (NYSE:ABBV) said Thursday that it is preparing for potential pharmaceutical sector tariffs, warning investors that trade headwinds could impact financial performance later this year. While the company raised its full-year earnings and revenue guidance, executives repeatedly highlighted tariff risk and broader U.S. government disruption as material uncertainties on its earnings call.",
    "url": "https://finnhub.io/api/news?id=d56ad53e32f9e740163711dd374a1214b415bd3214d81b639520e899c9e6634a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745595233,
      "headline": "AbbVie warns of tariff exposure, U.S. policy risks while boosting forecast",
      "id": 134087644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- AbbVie Inc (NYSE:ABBV) said Thursday that it is preparing for potential pharmaceutical sector tariffs, warning investors that trade headwinds could impact financial performance later this year. While the company raised its full-year earnings and revenue guidance, executives repeatedly highlighted tariff risk and broader U.S. government disruption as material uncertainties on its earnings call.",
      "url": "https://finnhub.io/api/news?id=d56ad53e32f9e740163711dd374a1214b415bd3214d81b639520e899c9e6634a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Raises Full-Year Outlook as First-Quarter Results Top Street Estimates",
    "summary": "AbbVie (ABBV) lifted its full-year outlook on Friday as the biopharmaceutical company recorded first",
    "url": "https://finnhub.io/api/news?id=97d57ee0f16696dcf4c56b12859ed5f19bf2f522029c288edbfa104b0c8b0b80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745592313,
      "headline": "AbbVie Raises Full-Year Outlook as First-Quarter Results Top Street Estimates",
      "id": 134087646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) lifted its full-year outlook on Friday as the biopharmaceutical company recorded first",
      "url": "https://finnhub.io/api/news?id=97d57ee0f16696dcf4c56b12859ed5f19bf2f522029c288edbfa104b0c8b0b80"
    }
  },
  {
    "ts": null,
    "headline": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
    "summary": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
    "url": "https://finnhub.io/api/news?id=5d8eac37b3293774beb7514478c3fc4cb9982fbb645b06af6eae409526b9565f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745591400,
      "headline": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
      "id": 134127344,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
      "url": "https://finnhub.io/api/news?id=5d8eac37b3293774beb7514478c3fc4cb9982fbb645b06af6eae409526b9565f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside",
    "summary": "AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, rising EPS, and strong dividend yield.",
    "url": "https://finnhub.io/api/news?id=559ba5dc91e1d5d074418cef8aefbc28282c7c9836759a2082b471af5e50283f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745589609,
      "headline": "AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside",
      "id": 134094622,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, rising EPS, and strong dividend yield.",
      "url": "https://finnhub.io/api/news?id=559ba5dc91e1d5d074418cef8aefbc28282c7c9836759a2082b471af5e50283f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet.",
    "summary": "First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts’ expectations.",
    "url": "https://finnhub.io/api/news?id=193e45593ee0e217d9df9f78b8b8bb572e773a36bbaf0fffdebef68da8827f47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745589600,
      "headline": "AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet.",
      "id": 134087648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts’ expectations.",
      "url": "https://finnhub.io/api/news?id=193e45593ee0e217d9df9f78b8b8bb572e773a36bbaf0fffdebef68da8827f47"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie, Schlumberger, Colgate-Palmolive: Trending tickers",
    "summary": "Here are some stocks on the move on April 25. AbbVie (ABBV) raised its 2025 profit forecast, citing the strength of some of the newer drugs in its immunology portfolio. Schlumberger (SLB) reported first quarter earnings that fell short of estimates. Colgate-Palmolive (CL) cut its full-year earnings outlook, citing tariff impacts. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=7c65297b5439aa42ca015f300564e0072854323d8208289e7e74ae61714fb44c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745589235,
      "headline": "AbbVie, Schlumberger, Colgate-Palmolive: Trending tickers",
      "id": 134087649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Here are some stocks on the move on April 25. AbbVie (ABBV) raised its 2025 profit forecast, citing the strength of some of the newer drugs in its immunology portfolio. Schlumberger (SLB) reported first quarter earnings that fell short of estimates. Colgate-Palmolive (CL) cut its full-year earnings outlook, citing tariff impacts. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=7c65297b5439aa42ca015f300564e0072854323d8208289e7e74ae61714fb44c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch on Friday: Alphabet, AbbVie, T-Mobile, Skechers",
    "summary": "↗️ Alphabet (GOOGL): Google's parent company reported quarterly operating income that solidly beat Wall Street's forecasts, while advertising revenue rose 8% on the year. Shares rallied Friday morning.",
    "url": "https://finnhub.io/api/news?id=20d572cf9b416b19d2940e6d433b3a8166713c78688cd7e4d2216336751e5503",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745588694,
      "headline": "Stocks to Watch on Friday: Alphabet, AbbVie, T-Mobile, Skechers",
      "id": 134087447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "↗️ Alphabet (GOOGL): Google's parent company reported quarterly operating income that solidly beat Wall Street's forecasts, while advertising revenue rose 8% on the year. Shares rallied Friday morning.",
      "url": "https://finnhub.io/api/news?id=20d572cf9b416b19d2940e6d433b3a8166713c78688cd7e4d2216336751e5503"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say",
    "summary": "Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=00dda81182be9f1823bbdb6682d1c56bd4aa7bd1149b165ca9ddd5387b94fe67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745587814,
      "headline": "AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say",
      "id": 134087653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=00dda81182be9f1823bbdb6682d1c56bd4aa7bd1149b165ca9ddd5387b94fe67"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie raises 2025 outlook after strong first-quarter sales growth",
    "summary": "AbbVie raises 2025 outlook after strong first-quarter sales growth",
    "url": "https://finnhub.io/api/news?id=066e2be8ef2acd04d664ac5429a761d616e46874ab1715a054e9ed7a0859011a",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745587191,
      "headline": "AbbVie raises 2025 outlook after strong first-quarter sales growth",
      "id": 134078122,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=066e2be8ef2acd04d664ac5429a761d616e46874ab1715a054e9ed7a0859011a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie lifts profit forecast, downplays tariff threat",
    "summary": "AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump...",
    "url": "https://finnhub.io/api/news?id=f61228e071d3aed388433c083352202a8847263d9fb884925938e6565e7393da",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745586039,
      "headline": "AbbVie lifts profit forecast, downplays tariff threat",
      "id": 134091950,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump...",
      "url": "https://finnhub.io/api/news?id=f61228e071d3aed388433c083352202a8847263d9fb884925938e6565e7393da"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates",
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=83aafd6c166ae14017f122ab18ac91e95ed2154ed6bc550c403a762ad79bc972",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745585702,
      "headline": "AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates",
      "id": 134087581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=83aafd6c166ae14017f122ab18ac91e95ed2154ed6bc550c403a762ad79bc972"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): One of the Growing Dividend Stocks with Low PE Ratios",
    "summary": "We recently published a list of the 30 Growing Dividend Stocks with Low PE Ratios. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other growing dividend stocks. Value stocks are enjoying a rare period of strength amid this year’s broader market downturn. With earnings season approaching, it […]",
    "url": "https://finnhub.io/api/news?id=9d068dbad68c747059fa9ffe69adfeb0430b43855bce6db09cdc158af3a75b0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745583709,
      "headline": "AbbVie Inc. (ABBV): One of the Growing Dividend Stocks with Low PE Ratios",
      "id": 134087658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published a list of the 30 Growing Dividend Stocks with Low PE Ratios. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other growing dividend stocks. Value stocks are enjoying a rare period of strength amid this year’s broader market downturn. With earnings season approaching, it […]",
      "url": "https://finnhub.io/api/news?id=9d068dbad68c747059fa9ffe69adfeb0430b43855bce6db09cdc158af3a75b0e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Reports Bullish Q1",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=079a85e38a81ee132d0edc0ec99cd28b75edccfa0f550033fa4fb3f24b22cafa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745583543,
      "headline": "AbbVie (NYSE:ABBV) Reports Bullish Q1",
      "id": 134087660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=079a85e38a81ee132d0edc0ec99cd28b75edccfa0f550033fa4fb3f24b22cafa"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript",
    "summary": "AbbVie Inc. (NYSE:ABBV) Q1 2025 - Earnings Conference Call April 25, 2025 9:00 PM ETCompany ParticipantsLiz Shea - Senior VP, IRRob Michael - CEOJeff...",
    "url": "https://finnhub.io/api/news?id=5fab241e71d2a8dcd24398fd9902341bc733d68d3ee67599f2f263a775975438",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745583261,
      "headline": "AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript",
      "id": 134089594,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) Q1 2025 - Earnings Conference Call April 25, 2025 9:00 PM ETCompany ParticipantsLiz Shea - Senior VP, IRRob Michael - CEOJeff...",
      "url": "https://finnhub.io/api/news?id=5fab241e71d2a8dcd24398fd9902341bc733d68d3ee67599f2f263a775975438"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q1 Earnings Snapshot",
    "summary": "The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $2.39 per share. The drugmaker posted revenue of $13.34 billion in the period, which also beat Street forecasts.",
    "url": "https://finnhub.io/api/news?id=06bd60f6d3b7692cc292f8c364ace0edaaa4c37afe084535e4ad921f1b9a8ab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745581929,
      "headline": "AbbVie: Q1 Earnings Snapshot",
      "id": 134087662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $2.39 per share. The drugmaker posted revenue of $13.34 billion in the period, which also beat Street forecasts.",
      "url": "https://finnhub.io/api/news?id=06bd60f6d3b7692cc292f8c364ace0edaaa4c37afe084535e4ad921f1b9a8ab9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie lifts profit forecast on strong sales of newer immunology drugs",
    "summary": "(Reuters) -AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped the company beat Wall Street estimates for first-quarter earnings, sending shares up more than 4% in premarket trading.  The company said its updated forecast did not reflect any trade policy shifts, including possible U.S. tariffs on the pharmaceutical sector.  The drugmaker's stock, along with that of its peers, have plummeted over the past month due to investor concerns around a probe into the sector as U.S. President Donald Trump's administration has sought to impose tariffs on the industry.",
    "url": "https://finnhub.io/api/news?id=fcaa10a8828d5194732ed25f7d848bc9c14b35d239dc599ced3275cf733249cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745581657,
      "headline": "AbbVie lifts profit forecast on strong sales of newer immunology drugs",
      "id": 134087663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Reuters) -AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped the company beat Wall Street estimates for first-quarter earnings, sending shares up more than 4% in premarket trading.  The company said its updated forecast did not reflect any trade policy shifts, including possible U.S. tariffs on the pharmaceutical sector.  The drugmaker's stock, along with that of its peers, have plummeted over the past month due to investor concerns around a probe into the sector as U.S. President Donald Trump's administration has sought to impose tariffs on the industry.",
      "url": "https://finnhub.io/api/news?id=fcaa10a8828d5194732ed25f7d848bc9c14b35d239dc599ced3275cf733249cb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Reports First-Quarter 2025 Financial Results",
    "summary": "AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2025.",
    "url": "https://finnhub.io/api/news?id=39d47c8b58492dd9820aa3c6a541acdb73de1a48867d0ffc263d2c92bac101ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745581380,
      "headline": "AbbVie Reports First-Quarter 2025 Financial Results",
      "id": 134087666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2025.",
      "url": "https://finnhub.io/api/news?id=39d47c8b58492dd9820aa3c6a541acdb73de1a48867d0ffc263d2c92bac101ef"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update",
    "summary": "By Denny Jacob AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the...",
    "url": "https://finnhub.io/api/news?id=8185c74027a63ec06ce42fa46c0ba08c1beb182a29691b9d12bed0cf8f17e376",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745575087,
      "headline": "AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update",
      "id": 134079433,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Denny Jacob AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the...",
      "url": "https://finnhub.io/api/news?id=8185c74027a63ec06ce42fa46c0ba08c1beb182a29691b9d12bed0cf8f17e376"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?",
    "summary": "Biogenâs lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=ef3adb4bcd126997d1f1592527ecb2afc521115bd3cda32b4212595c2984fefe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745572551,
      "headline": "Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?",
      "id": 134077371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724853/image_2165724853.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Biogenâs lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=ef3adb4bcd126997d1f1592527ecb2afc521115bd3cda32b4212595c2984fefe"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised",
    "summary": "By Denny Jacob AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the...",
    "url": "https://finnhub.io/api/news?id=7120b50fa69a106c2243b553e0118af906e13df843f92e7b75181888e8e2175a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745571201,
      "headline": "AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised",
      "id": 134075472,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Denny Jacob AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the...",
      "url": "https://finnhub.io/api/news?id=7120b50fa69a106c2243b553e0118af906e13df843f92e7b75181888e8e2175a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: EPS target range raised for 2025",
    "summary": "Alongside the publication of its quarterly results, AbbVie announced a ten-cent increase in its adjusted EPS target range for 2025 to between $12.09 and $12.29, although these targets are based on the...",
    "url": "https://finnhub.io/api/news?id=f7a4a9115d00ec471e58bda7cfda3d1b20de0e151cba2c43aca5da4970f61596",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745569699,
      "headline": "AbbVie: EPS target range raised for 2025",
      "id": 134074794,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Alongside the publication of its quarterly results, AbbVie announced a ten-cent increase in its adjusted EPS target range for 2025 to between $12.09 and $12.29, although these targets are based on the...",
      "url": "https://finnhub.io/api/news?id=f7a4a9115d00ec471e58bda7cfda3d1b20de0e151cba2c43aca5da4970f61596"
    }
  },
  {
    "ts": null,
    "headline": "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV",
    "summary": "NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=af84c2ebc084000d6b1f3a63837ae81522cb054b3d4d08c7d22e49c125ad0a95",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745559980,
      "headline": "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV",
      "id": 134070315,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=af84c2ebc084000d6b1f3a63837ae81522cb054b3d4d08c7d22e49c125ad0a95"
    }
  }
]